mRNA Display Pipeline for Protein Biosensor Construction.
Zhenling CuiCagla Ergun AyvaYi Jin LiewZhong GuoRoxane MutschlerBirgit DreierMaria M FioritoPatricia WaldenChristopher B HowardFernanda ElyAndreas PlückthunCarel PretoriusJacobus Pj UngererAshley M BuckleKirill AlexandrovPublished in: ACS sensors (2024)
Despite the significant potential of protein biosensors, their construction remains a trial-and-error process. The most obvious approach for addressing this is to utilize modular biosensor architectures where specificity-conferring modalities can be readily generated to recognize new targets. Toward this goal, we established a workflow that uses mRNA display-based selection of hyper-stable monobody domains for the target of choice or ribosome display to select equally stable DARPins. These binders were integrated into a two-component allosteric biosensor architecture based on a calmodulin-reporter chimera. This workflow was tested by developing biosensors for liver toxicity markers such as cytosolic aspartate aminotransferase, mitochondrial aspartate aminotransferase, and alanine aminotransferase 1. We demonstrate that our pipeline consistently produced >10 3 unique binders for each target within a week. Our analysis revealed that the affinity of the binders for their targets was not a direct predictor of the binder's performance in a biosensor context. The interactions between the binding domains and the reporter module affect the biosensor activity and the dynamic range. We conclude that following binding domain selection, the multiplexed biosensor assembly and prototyping appear to be the most promising approach for identifying biosensors with the desired properties.
Keyphrases
- label free
- sensitive detection
- gold nanoparticles
- quantum dots
- binding protein
- small molecule
- oxidative stress
- clinical trial
- randomized controlled trial
- single cell
- risk assessment
- dna binding
- protein protein
- electronic health record
- climate change
- protein kinase
- mass spectrometry
- phase iii
- human health
- open label
- high density
- double blind